Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

1. Neoadjuvant pembrolizumab allows many CSCC patients to avoid surgery. 2. 63% achieved clinical/pathologic complete response. 3. Study emphasized the importance of multimodal response assessment. 4. Patients received 4 cycles of pembrolizumab. 5. 74% event-free survival at 18 months. 6. Adverse events reported in 89% of patients, mostly fatigue and pruritus. 7. Results prompt questions about de-escalation of therapy.